Connexin hemichannel induced vascular leak suggests a new paradigm for cancer therapy

Jie Zhang1, Simon J O'Carroll2, Kimiora Henare3

  • 1Department of Ophthalmology and New Zealand National Eye Centre, Faculty of Medical and Health Sciences, University of Auckland, Private Bag 92019, Auckland, New Zealand.

FEBS Letters
|February 20, 2014
PubMed

Insights

Targeting tumor blood vessels with anti-angiogenic drugs has yielded disappointing results. This study suggests protecting, not blocking, tumor vasculature using connexin channel modulation may improve cancer therapy and patient outcomes.

Area of Science:

  • Oncology
  • Vascular Biology
  • Cellular Biology

Background:

  • Neovascularization is crucial for tumor growth, yet anti-angiogenic therapies have shown limited success and emerging toxicities.
  • Gap junction channels and connexins play roles in vascular integrity, wound healing, and inflammatory diseases.
  • Vascular disruption in chronic eye conditions shares similarities with tumor vasculature.

Purpose of the Study:

  • To review the role of connexins in vascular leak and endothelial cell death.
  • To explore the potential of connexin hemichannel modulation in preventing vascular disruption.
  • To propose a novel therapeutic strategy of protecting tumor vasculature.

Main Methods:

  • Review of existing literature on connexins, vascular biology, and anti-angiogenic therapies.
  • Analysis of vascular disruption in wound healing, ocular diseases, and cancer.
  • Application of findings from non-cancerous conditions to tumor vessel biology.

Main Results:

  • Connexin channel blockers can improve healing by preventing vascular disruption and restoring vascular integrity.
  • Vascular changes in chronic inflammatory eye disorders resemble those in tumors.
  • Connexin hemichannel modulation can prevent vascular disruption in ocular conditions.

Conclusions:

  • Current anti-angiogenic strategies targeting tumor vasculature may be misguided.
  • Protecting and restoring tumor vasculature, rather than inhibiting it, could be a beneficial therapeutic approach.
  • Modulating connexin hemichannels offers a potential strategy to improve cancer treatment efficacy by reducing hypoxia and enhancing drug/radiation delivery.

Related Concept Videos

Overview of Cell-Matrix Interactions01:24

Overview of Cell-Matrix Interactions

The extracellular matrix or ECM holds cells together to form a tissue and allows the cells within the tissue to communicate. ECM comprises proteins such as fibronectin, collagen, laminin, etc. The most abundant protein in this space is collagen. Collagen fibers are interwoven with carbohydrate-containing protein molecules called proteoglycans. ECM allows cell migration and provides a structural scaffold at cell adhesion that anchors the cell when the extracellular matrix proteins interact with...
8.0K
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.9K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.7K
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
6.4K
Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.4K
Cancer Cell Migration through Invadopodia01:35

Cancer Cell Migration through Invadopodia

Invadosome is a broad category of cell surface structures with proteolytic activity that  degrades the extracellular matrix (ECM). Invadosomes are present in normal cell types, including macrophages, endothelial cells, and neurons, as well as tumor cells. Although the macrophage podosomes and tumor cell invadopodia are classified as invadosomes, they have different structures, molecular pathways, and functions. Podosomes are short structures that last for a few minutes. However,...
2.5K